Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa Therapeutics, Inc. (ATOS) recently announced promising safety and efficacy data from the company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.(Z)-endoxifen is being assessed as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer as part of the EVANGELINE research.More on the EVANGELINE StudyIn Phase 2 EVANGELINE study, participants are likely to recei ...